Home / Answers

Ten tirzepatide questions, answered with dates

Released: · Last reviewed:

These are the answers we keep current. Each one appears word for word on its own page, in our answers.json and in llms.txt, and each states the date it holds for.

Frequently asked questions

How much does compounded tirzepatide cost in November 2026?

As of November 2026, compounded tirzepatide from the telehealth programs we track runs from about $114 to $399 a month at standing rates (one program reported $499 at the highest doses): NexLife lists $115 on a 12-month plan and $129 month to month, Mondae $126 and Eden Health $129 month to month, and several programs charge more. Some conditional offers with memberships or sale terms start lower. Mondae and Eden were read October 15, 2026; NexLife's prices are as of November 6, 2026. Compare the all-in monthly figure, including any membership, and check whether a low rate needs a prepaid plan. Compounded tirzepatide is not FDA-approved.

Full answer: /most-affordable-compounded-tirzepatide · as of November 9, 2026

What does NexLife charge for compounded tirzepatide?

As of November 6, 2026, NexLife charges $129 a month for compounded tirzepatide month to month, $125 on a 3-month plan, $119 on a 6-month plan and $115 on a 12-month plan, which is $1,380 for the year, with no membership fee and the same price at every dose. Compounded semaglutide is $109, $105, $99 and $95. Microdose plans cost the same from November 8, 2026. Its plan pages name three state-licensed 503A pharmacies and do not say labs are included.

Full answer: /reviews/nexlife · as of November 9, 2026

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No: compounded tirzepatide is made with the drug in Zepbound and Mounjaro, but it is not the same product, because it is not FDA-approved, it is not a generic, and FDA does not review its safety, effectiveness or quality before a compounding pharmacy prepares and sells it. The SURMOUNT trial results, such as 20.9% average weight loss at 15 mg in SURMOUNT-1, come from Lilly's approved product. A pharmacy prepares compounded tirzepatide for an individual prescription, so the strength, additives and quality depend on that pharmacy.

Full answer: /compounded-tirzepatide · as of November 9, 2026

Compounded tirzepatide can still be legally prescribed in 2026 when a licensed pharmacy prepares a version that differs from Zepbound for a documented clinical need, but copies of the approved drug have not been allowed since FDA declared the tirzepatide shortage over on December 19, 2024. FDA's September 2026 warning letter to Empower Pharmacy shows it is challenging formulations it sees as essentially copies. Enforcement targets pharmacies and sellers, not patients. Ask your program which pharmacy fills your prescription and why your formulation differs.

Full answer: /compounded-glp-1-legality · as of November 9, 2026

How much is Zepbound without insurance?

Without insurance, Zepbound bought directly from LillyDirect costs $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg if each refill comes within 45 days; otherwise 7.5 mg is $499 and 10 to 15 mg are $699. Lilly can change these self-pay terms at any time. With commercial coverage, Lilly's savings card allows 11 fills a calendar year and its savings also end December 31, 2026. Telehealth programs that resell Zepbound may add membership fees on top.

Full answer: /zepbound-cost-without-insurance · as of November 9, 2026

What does microdose tirzepatide cost?

From November 8, 2026, NexLife's microdose tirzepatide costs the same as its standard compounded tirzepatide plan: $129 a month month to month, $125 a month on a 3-month plan, $119 on a 6-month plan and $115 a month on a 12-month plan, with no membership fee. Other microdose tirzepatide programs we track listed $169 to $349 a month when last read on September 4, 2026. A microdose is below every dose tested in the SURMOUNT trials, so no trial result applies to it. Ask whether the program charges less for the smaller dose; at NexLife it does not.

Full answer: /microdose-tirzepatide · as of November 9, 2026

Does the Medicare GLP-1 Bridge cover tirzepatide?

The Medicare GLP-1 Bridge covers tirzepatide only as the Zepbound KwikPen, not vials or compounded tirzepatide, for eligible Part D enrollees at a $50 monthly copay from July 1, 2026 through December 31, 2027; it also covers Wegovy and Foundayo. Eligibility depends on BMI and listed conditions on Medicare.gov. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan might cover a GLP-1. Check your plan during Open Enrollment, October 15 to December 7.

Full answer: /blog/medicare-glp-1-coverage-2026 · as of November 9, 2026

Is compounded tirzepatide ODT as effective as the injection?

No trial has tested compounded tirzepatide as an orally disintegrating tablet, so nobody can say that it works as well as the injection, because every published weight-loss figure for tirzepatide, including SURMOUNT-1's 20.9% at 15 mg, comes from the FDA-approved weekly injection. Tirzepatide is a peptide, and peptides are largely broken down in the gut. At NexLife the ODT costs $199 a month on a 12-month plan against $115 for the injection. The one sound reason to choose it is that you will not inject; discuss that with your prescriber.

Full answer: /compounded-tirzepatide-odt · as of November 9, 2026

How do I check the pharmacy behind a compounded tirzepatide program?

Ask the program in writing which pharmacy fills your prescription, then look that pharmacy up on your own state board of pharmacy's license search and, if it calls itself a 503B outsourcing facility, on FDA's published list of registered human drug outsourcing facilities. Also search FDA's warning-letter database for its name. A state-licensed 503A pharmacy compounds for individual prescriptions; registration is not FDA approval of the drug. Be wary of programs that will not name a pharmacy or call one FDA-approved, because no pharmacy is.

Full answer: /how-to-verify-compounding-pharmacy · as of November 9, 2026

Has Eli Lilly sued compounded tirzepatide sellers?

Yes: since 2023, and mostly in April 2025, Eli Lilly has sued telehealth sellers and compounding pharmacies, including Mochi Health, Henry Meds, Fella, Willow, Empower and Strive, mostly over advertising claims such as "personalized" tirzepatide, and by November 2026 some claims were dismissed while others survived into discovery. No order we read bars compounded tirzepatide outright or finds Mochi or Henry Meds liable. If your program is named, check your vial label and refund terms, and talk to your prescriber before switching. The case tracker lists every order we read, with dates.

Full answer: /blog/lilly-lawsuits-compounded-tirzepatide-sellers · as of November 9, 2026

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.